www.fdanews.com/articles/113485-approval-in-canada-to-begin-two-phase-ii-trials-of-nimotuzumab

Approval in Canada to Begin Two Phase II Trials of Nimotuzumab

January 6, 2009

YM BioSciences Inc. has received clearance from Canadian regulatory authorities to initiate two Phase II, double-blind, randomized trials for nimotuzumab, its EGFR-targeting antibody, in combination with radiation-based treatments.
TradingMarkets